BioNTech and Pfizer have applied to the European Medicines Agency for permission for the coronavirus vaccine they have developed.
This is intended to be used in children between the ages of 12 and 15 years.
BioNTech has submitted a statement about the request to the European Medicines Agency (EMA).
According to the statement, an application has been submitted to the US Food and Drug Administration (FDA) for an “emergency use permit.”
-Advertisement-
The company also recently announced that its clinical study of 260,000 people between the ages of 12 and 15 in the United States showed 100 percent efficiency.
He explained in the statement that the side effects will be the same as those in the 16-25 age group.
If approved by the EMA, children between 12 and 15 years of age are planned to be vaccinated in 27 European Union countries in mid-June.
The protection rate from the BioNTech vaccine is over 90 percent
Scientific assessments are to be expected
European Union officials have reported that they are awaiting the results of scientific assessments and studies to apply the BioNTech – Pfizer vaccine to children.
Recalling that they are negotiating the purchase of an additional 1.8 billion doses of the BioNTech – Pfizer vaccine for European Union countries.
Eric Mamer, a spokesperson for the European Union Commission, has said that they will have sufficient doses to vaccinate children if the EMA is approved.
Mamer rejected criticism that the European Union Commission had not taken into account children within the Union’s borders in vaccination.
